Latest Content

GLP-1s and SGLT2s were associated with improved kidney outcomes and no increased safety risks in patients with T1D and CKD.

A survey of marketplace enrollees revealed that they expect to cut back on basic household expenses to keep insurance coverage.

Male patients and those from minoritized racial and ethnic groups face longer times to treatment, especially in urban areas.

One in 4 Medicaid managed care organization sanctions are not remediated, revealing inconsistent state and federal oversight and the need to standardize CMS reporting and enforcement guidelines.

Patients with primary biliary cholangitis (PBC) can use linerixibat to address cholestatic pruritus, which up to 89% of patients with PBC experience.

A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and immunogenicity to reference ustekinumab in patients with moderate to severe plaque psoriasis.

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery.

A new meta-analysis links menopausal hormone therapy to higher breast cancer risk with estrogen-progestin therapy, while estrogen-only therapy may lower risk.

New research shows that cardiovascular protection from GLP-1 receptor agonists such as semaglutide and tirzepatide diminishes within months of discontinuation.